Abstracts tagged "pain"

Abstract Number: 0912 • ACR Convergence 2022
Associations Between Fatty Acid Amide Hydrolase Variants and Response to Cannabis Use for Pain Management in Rheumatoid Arthritis
Kristin Wipfler¹, Joanna Zeiger², Teresa Simon³, Stuart Kassan⁴ and Kaleb Michaud⁵, ¹FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ²Canna Research Foundation, Boulder, CO, ³Physicians Research Center Consultant to ForWard, Toms River, NJ, ⁴Colorado Arthritis Associates, Lakewood, CO, ⁵University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Fatty acid amide hydrolase (FAAH) is a serine hydrolase that breaks down the endocannabinoid/cannabinoid receptor agonist anandamide. Variants in the FAAH gene have been…
Abstract Number: 1499 • ACR Convergence 2022
The Impact of Cycling Among Tumor Necrosis Factor Inhibitors on Disease Control in Patients with Axial Spondyloarthritis: A Study from the CorEvitas PsA/SpA Registry
Philip J Mease¹, Robert McLean², Taylor Blachley², Nicole Middaugh², Manish Mittal³, Jerry Clewell³, Heather Jones⁴ and Alexis Ogdie⁵, ¹Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ²CorEvitas, LLC, Waltham, MA, ³AbbVie, Inc., North Chicago, IL, ⁴AbbVie, Inc., Chicago, IL, ⁵Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Axial spondyloarthritis (AxSpA) is a chronic inflammatory disease characterized by inflammatory back pain, morning stiffness, and reduced functional capacity. Approved therapies for AxSpA include…
Abstract Number: 1891 • ACR Convergence 2022
Osteoarthritis of the Knee, Inflammation, and the Effect of Adalimumab: A Randomized Placebo-Controlled Trial
Walter P Maksymowych¹, Louis Bessette², Robert G Lambert³, Amanda Carapellucci⁴ and Tom Appleton⁵, ¹Department of Medicine, University of Alberta, Edmonton, AB, Canada, ²Centre de l'Ostoporose et de Rhumatologie de Québec, Québec, QC, Canada, ³University of Alberta, Edmonton, AB, Canada, ⁴CARE Arthritis LTD, Edmonton, AB, Canada, ⁵The University of Western Ontario, London, ON, Canada
Background/Purpose: Recent RCTs demonstrated that TNFα inhibition has no effect on pain and MRI-detected synovitis or bone marrow lesions in patients with erosive hand OA.…
Abstract Number: 1992 • ACR Convergence 2022
Burden of Pain for Patients in the CorEvitasTM Rheumatoid Arthritis Registry
Joshua Baker¹, J Morel Symons², Jud C Janak³, Page Moore³, Elizabeth Kohl³, Bernice Gershenson³, Oksana Pugach³, Dave Webb⁴, Alan A Martin⁴, Didier Saurigny⁵ and Marguerite Bracher⁵, ¹University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, ²GlaxoSmithKline, Collegeville, PA, ³CorEvitas, LLC, Waltham, MA, ⁴GlaxoSmithKline, Brentford, United Kingdom, ⁵GlaxoSmithKline, Stevenage, United Kingdom
Background/Purpose: Pain is a hallmark symptom of RA that impacts patients' quality of life and informs therapeutic decisions that aim to reduce joint inflammation and…
Abstract Number: 0016 • ACR Convergence 2021
Structural and Functional Neurobiological Alterations of Salience and Sensorimotor Networks in Juvenile Idiopathic Arthritis
Hanne van der Heijden¹, Jordan Lemme², Mariesa Cay², Diana Sibai², Benjamin Goodlett³, Jeffrey Lo⁴, Peter Nigrovic⁵, Margaret Chang⁴, Esra Meidan⁴, Olha Halyabar⁴, Melissa Hazen⁶, Maria Taylor⁴, Kacie Hoyt⁴, Camilo Jaimes⁷, Lauren Henderson³, Kirsten Ecklund⁷, Rudy Schreiber⁸, Robert Sundel⁴ and Jaymin Upadhyay⁹, ¹Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children’s Hospital, Harvard Medical School, Boston, MA USA/ Faculty of Psychology and Neuroscience, Section Neuropsychology & Psychopharmacology Maastricht University, Maastricht, The Netherlands/ Faculty of Science, Biomedical Sciences Neurobiology, University of Amsterdam, Amsterdam, The Netherlands, Sittard, Netherlands, ²Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children’s Hospital, Harvard Medical School, Boston, MA USA, Boston, MA, ³Division of Genetics and Genomics, Boston Children’s Hospital, Harvard Medical School, Boston, MA, ⁴Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, ⁵Boston Children's Hospital, Brookline, MA, ⁶Boston Children's Hospital, Boston, MA, ⁷Department of Radiology, Boston Children’s Hospital, Harvard Medical School, Boston, ⁸Faculty of Psychology and Neuroscience, Section Neuropsychology & Psychopharmacology Maastricht University, Maastricht, The Netherlands., Maastricht, Netherlands, ⁹Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children’s Hospital, Harvard Medical School, Boston, MA USA/ Department of Psychiatry, McLean Hospital, Harvard Medical School, Belmont, MA USA, Boston, MA
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is a common childhood illness, characterized by inflammation of the joint, chronic pain and decreased physical functioning. To date, the…
Abstract Number: 0718 • ACR Convergence 2021
Pain Severity and Interference in Adult Autoimmune Inflammatory Myopathies
Harmony Tsui¹, Mianbo Wang², Mathieu Piché³, Alexandra Ladouceur⁴, Evelyne Vinet⁵, Alexandra Albert⁶, Maggie Larche⁷, Annaliese Tisseverasinghe⁸, Marie Hudson¹ and Valerie Leclair⁹, ¹McGill University, Montréal, QC, Canada, ²Lady Davis institute for Medical Research, Montréal, QC, Canada, ³Université du Québec à Trois-Rivières, Trois-Rivières, QC, Canada, ⁴McGill University Health Center, Montréal, QC, Canada, ⁵McGill University Health Centre, Mont Royal, QC, Canada, ⁶CHU de Quebec, Québec City, QC, Canada, ⁷McMaster University, Hamilton, ON, Canada, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹McGill University, Karolinska Insitutet, Montréal, QC, Canada
Background/Purpose: Although pain is one of the most common and highest priority symptoms reported by people with autoimmune inflammatory myopathies (AIM), large descriptive studies on…
Abstract Number: 1124 • ACR Convergence 2021
Examining the Relationships Between Treatment and Pain and Physical Function Outcomes in Patients with Osteoarthritis: A Mediation Modeling Approach
Lucy Abraham¹, Robert Dworkin², Dennis C. Turk³, John D. Markman², David A. Williams⁴, Andrew G Bushmakin⁵, Jerry A. Hall⁶, David C. Semel⁷, Joseph C Cappelleri⁵ and Ruoyong Yang⁸, ¹Pfizer Ltd., Tadworth, United Kingdom, ²University of Rochester, Rochester, NY, ³University of Washington, Seattle, WA, ⁴University of Michigan, Ann Arbor, MI, ⁵Pfizer Inc, Groton, CT, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Pfizer, New York, NY, ⁸Pfizer Inc., New York, NY
Background/Purpose: To better understand the complex relationships between treatment and pain and physical function (PF) outcomes, we investigated a set of mediation models of osteoarthritis…
Abstract Number: 1614 • ACR Convergence 2021
Preliminary Results from a Pilot Feasibility and Acceptability Trial of Resilience Coaching for Adolescent Chronic Musculoskeletal Pain
Sabrina Gmuca¹, Pamela Weiss¹, Mackenzie McGill¹, Maitry Sonagra², David D. Sherry¹, Peter Cronholm³, Jeffrey S. Gerber¹, Tonya M. Palermo⁴, Jami F. Young¹ and Abby R. Rosenberg⁴, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Children's Hospital of Philadelphia, Cherry Hill, NJ, ³University of Pennsylvania, Philadelphia, PA, ⁴Seattle Children's Hospital, Seattle, WA
Background/Purpose: Chronic musculoskeletal pain (CMP) affects up to 40% of youth and is associated with physical disability and psychological distress. Resilience coaching interventions, such as…
Abstract Number: 0118 • ACR Convergence 2021
Multidimensional Phenotypes of Sleep Quality Using the Pittsburg Quality Sleep Index and Associations Among Sleep Dimensions and Symptoms in Women Diagnosed with Fibromyalgia
Victoria Menzies, Debra Lynch Kelly and Miichael Weaver, University of Florida, Gainesville, FL
Background/Purpose: There are over 10 million people in the United States suffering with fibromyalgia syndrome (FMS). Individuals with FMS typically report multiple concurrent symptoms including…
Abstract Number: 0723 • ACR Convergence 2021
Size of Regression to the Mean in First-Line Interventions for Osteoarthritis: An Illusion of Effectiveness
Martin Englund and Aleksandra Turkiewicz, Lund University, Lund, Sweden
Background/Purpose: Persons who seek treatment for osteoarthritis (OA) are likely doing so when experiencing a flare-up in pain. Due to natural fluctuation of pain, this…
Abstract Number: 1166 • ACR Convergence 2021
Marijuana Use Amongst Rheumatology Patients: It’s More Common Than Rheumatologists Believe
Rebecca Fitzpatrick¹, Najia Shakoor², Michael Grant² and Sonali Khandelwal², ¹Rush University Medical Center, Chicago, IL, ²Rush University, Chicago, IL
Background/Purpose: With the legalization of marijuana in many states, rheumatologists are having increased inquiries from patients regarding marijuana use in addition to their pain regimen.…
Abstract Number: 1617 • ACR Convergence 2021
Burden of Adverse Childhood Experiences in Pediatric Chronic Pain and Rheumatic Disease
Maitry Sonagra¹, Jeremy Jones², Mackenzie McGill³ and Sabrina Gmuca³, ¹Seattle Children's Hospital, Seattle, WA, ²University of Pennsylvania, Philadelphia, PA, ³Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Adverse childhood experiences (ACEs) serve as stressors that can have negative, lasting effects on health and wellbeing. While there has been increasing evidence to…
Abstract Number: 0121 • ACR Convergence 2021
The Efficacy of Group Behavioral Activation versus Usual Treatment in Patients with Fibromyalgia and Major Depression
Josefina Duran, Alvaro Verges, Ana Rocío Vázquez-Taboada, Matias Gonzalez and Lydia Gomez-Pérez, Pontificia Universidad Católica de Chile, Santiago, Chile
Background/Purpose: Fibromyalgia (FM) and major depression frequently coexist. Patients with both conditions have a worse prognosis and higher disability, and their treatment options are scarce.…
Abstract Number: 0724 • ACR Convergence 2021
Dose (Exposure) Efficacy Response of Tanezumab Following Intravenous and Subcutaneous Administration Across Phase 2 and Phase 3 Studies in Patients with Osteoarthritis of Hip and Knee
Martin Boucher¹, Kenneth Verburg², Puneet Gaitonde² and Scott marshall¹, ¹Pfizer R&D Ltd., Sandwich, United Kingdom, ²Pfizer Inc., Groton, CT
Background/Purpose: Tanezumab is a humanized monoclonal antibody against nerve growth factor that has been evaluated for relief of chronic osteoarthritis pain by subcutaneous (SC) or…
Abstract Number: 1200 • ACR Convergence 2021
Predicting Progression to RA in Patients with Seropositive Arthralgia
Aine Gorman¹, Keelin Flynn², Matthew Turk¹, Candice Low³, Kieran Murray⁴, Carl Orr⁵, Phil Gallagher⁵, Lorna Freeman², Edel Meaney², Eamonn Molloy⁶, Lorraine O Neill⁷, Ursula Fearon⁸ and Douglas Veale⁹, ¹St Vincents Hospital, Dublin, Ireland, ²The Centre for Arthritis and Rheumatic Disease, EULAR Centre of Excellence, St. Vincent’s University Hospital and University College Dublin, Ireland, Dublin, Ireland, ³St. Vincent's University Hospital, Dublin, Ireland, ⁴Saint Vincent's University Hospital, Dublin, Ireland, ⁵St Vincent's Hospital, Dublin, Ireland, ⁶St Vincent's Healthcare Group, Dublin, Ireland, ⁷St. Vincent's Hospital, Dublin, Ireland, ⁸Trinity College Dublin, Dublin, Ireland, ⁹University College Dublin, Dublin, Ireland
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic inflammatory condition often associated with joint destruction, disability, and reduced life expectancy. Before RA diagnosis, some patients may…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].